The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Pharmacological Treatment of Parkinson Disease: A Review
Abstract
IMPORTANCE: Parkinson disease is the second most common neurodegenerative disease worldwide. Although no available therapies alter the underlying neurodegenerative process, symptomatic therapies can improve patient quality of life. OBJECTIVE: To provide an evidence-based review of the initial pharmacological management of the classic motor symptoms of Parkinson disease; describe management of medication-related motor complications (such as motor fluctuations and dyskinesia), and other medication adverse effects (nausea, psychosis, and impulse control disorders and related behaviors); and discuss the management of selected nonmotor symptoms of Parkinson disease, including rapid eye movement sleep behavior disorder, cognitive impairment, depression, orthostatic hypotension, and sialorrhea. EVIDENCE REVIEW: References were identified using searches of PubMed between January 1985 and February 2014 for English-language human studies and the full database of the Cochrane Library. The classification of studies by quality (classes I-IV) was assessed using the levels of evidence guidelines from the American Academy of Neurology and the highest-quality data for each topic. RESULTS: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications. Motor fluctuations may be managed by modifying the levodopa dosing regimen or by adding several other medications, such as MAOBIs, catechol-O-methyltransferase inhibitors, or dopamine agonists. Impulse control disorders are typically managed by reducing or withdrawing dopaminergic medication, particularly dopamine agonists. Evidence-based management of some nonmotor symptoms is limited by a paucity of high-quality positive studies. CONCLUSIONS AND RELEVANCE: Strong evidence supports using levodopa and dopamine agonists for motor symptoms at all stages of Parkinson disease. Dopamine agonists and drugs that block dopamine metabolism are effective for motor fluctuations and clozapine is effective for hallucinations. Cholinesterase inhibitors may improve symptoms of dementia and antidepressants and pramipexole may improve depression. Evidence supporting other therapies for motor and nonmotor features is less well established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,246
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Self-citationImpulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients
Weintraub, D., Koester, J., Potenza, M. N., Siderowf, A. D., Stacy, M., Voon, V., Whetteckey, J., Wunderlich, G. R., & Lang, A. E. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.65 · Cited by 1,487
Self-citationAhlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Barone, P., Antonini, A., Colosimo, C., Marconi, R., Morgante, L., Avarello, T. P., Bottacchi, E., Cannas, A., Ceravolo, G., Ceravolo, R., et al. (2009) · Movement Disorders · doi:10.1002/mds.22643 · Cited by 1,445
Neurostimulation for Parkinson's Disease with Early Motor Complications
Schuepbach, W. M. M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Hälbig, T. D., Hesekamp, H., Navarro, S. M., Meier, N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205158 · Cited by 1,430
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Chronic Behavioral Disorders of Human REM Sleep: A New Category of Parasomnia
Schenck, C. H., Bundlie, S. R., Ettinger, M. G., & Mahowald, M. W. (1986) · Sleep · doi:10.1093/sleep/9.2.293 · Cited by 1,150
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Self-citationPoewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Self-citationBloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease
Mahoney-Sánchez, L., Bouchaoui, H., Ayton, S., Devos, D., Duce, J. A., & Devedjian, J.-C. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101890 · Cited by 553
Tapeinos, C., Battaglini, M., & Ciofani, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.033 · Cited by 539
Schenkman, M., Moore, C. G., Kohrt, W. M., Hall, D. A., Delitto, A., Comella, C. L., Josbeno, D. A., Christiansen, C. L., Berman, B. D., Kluger, B. M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3517 · Cited by 515
Visual dysfunction in Parkinson’s disease
Weil, R. S., Schrag, A. E., Warren, J. D., Crutch, S. J., Lees, A. J., & Morris, H. R. (2016) · Brain · doi:10.1093/brain/aww175 · Cited by 481
“General advice is to consider visuo-perceptual ability and if there is any doubt, to refer the patient for a formal driving assessment via the national driving authority (Crizzle et al., 2012).”
BackgroundReich, S. G., & Savitt, J. M. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.014 · Cited by 483
Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S., & Li-Hua, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 469
An update on the diagnosis and treatment of Parkinson disease
Rizek, P., Kumar, N., & Jog, M. S. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.151179 · Cited by 447
FTH1 Inhibits Ferroptosis Through Ferritinophagy in the 6-OHDA Model of Parkinson's Disease
Tian, Y., Lu, J., Hao, X., Li, H., Zhang, G., Liu, X., Li, X., Zhao, C., Kuang, W., Chen, D., et al. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00929-z · Cited by 422
Kwok, J. Y. Y., Kwan, J. C. Y., Auyeung, M., Mok, V. C. T., Lau, C. K. Y., Choi, K. C., & Chan, H. Y. L. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0534 · Cited by 379
Parkinson's disease: Autoimmunity and neuroinflammation
De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M. I., Gallo, A., Conte, M., Rosato, C., Ciniglio Appiani, M., & de Vincentiis, M. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.022 · Cited by 389
Improvement and Decline in Vision with Gene Therapy in Childhood Blindness
Jacobson, S. G., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Schwartz, S. B., Heon, E., & Hauswirth, W. W. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412965 · Cited by 372
Targeting voltage-gated calcium channels in neurological and psychiatric diseases
Zamponi, G. W. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.5 · Cited by 368
Freezing of gait: a practical approach to management
Nonnekes, J., Snijders, A. H., Nutt, J. G., Deuschl, G., Giladi, N., & Bloem, B. R. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00041-1 · Cited by 365
Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
Verschuur, C. V. M., Suwijn, S. R., Boel, J. A., Post, B., Bloem, B. R., van Hilten, J. J., van Laar, T., Tissingh, G., Munts, A. G., Deuschl, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809983 · Cited by 353
Self-citationWang, Y., Tong, Q., Ma, S.-R., Zhao, Z.-X., Pan, L.-B., Cong, L., Han, P., Peng, R., Yu, H., Lin, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00456-5 · Cited by 319
How to make a midbrain dopaminergic neuron
Arenas, E., Denham, M., & Villaescusa, J. C. (2015) · Development · doi:10.1242/dev.097394 · Cited by 308
The future of stem cell therapies for Parkinson disease
Parmar, M., Grealish, S., & Henchcliffe, C. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0257-7 · Cited by 306
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 300
Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease
Church, F. C. (2021) · Biomolecules · doi:10.3390/biom11040612 · Cited by 290
Ramesh, S., & Arachchige, A. S. P. M. (2023) · AIMS Neuroscience · doi:10.3934/neuroscience.2023017 · Cited by 289
Kustrimovic, N., Comi, C., Magistrelli, L., Rasini, E., Legnaro, M., Bombelli, R., Aleksic, I., Blandini, F., Minafra, B., Riboldazzi, G., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1248-8 · Cited by 278
Lastres-Becker, I., García-Yagüe, A. J., Scannevin, R. H., Casarejos, M. J., Kügler, S., Rábano, A., & Cuadrado, A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6549 · Cited by 274
Activation of the reward system boosts innate and adaptive immunity
Ben-Shaanan, T. L., Azulay-Debby, H., Dubovik, T., Starosvetsky, E., Korin, B., Schiller, M., Green, N. L., Admon, Y., Hakim, F., Shen-Orr, S. S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4133 · Cited by 272
Depression in neurodegenerative diseases: Common mechanisms and current treatment options
Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.002 · Cited by 269
Quality of life in Parkinson's disease: A systematic review and meta‐analysis of comparative studies
Zhao, N., Yang, Y., Zhang, L., Zhang, Q., Balbuena, L., Ungvari, G. S., Zang, Y., & Xiang, Y. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13549 · Cited by 265
Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis
Stinton, C., McKeith, I., Taylor, J.-P., Lafortune, L., Mioshi, E., Mak, E., Cambridge, V., Mason, J., Thomas, A., & O’Brien, J. T. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14121582 · Cited by 264
Pahuja, R., Seth, K., Shukla, A., Shukla, R. K., Bhatnagar, P., Chauhan, L. K. S., Saxena, P. N., Arun, J., Chaudhari, B. P., Patel, D. K., et al. (2015) · ACS Nano · doi:10.1021/nn506408v · Cited by 260
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease
Zhang, Q.-S., Heng, Y., Mou, Z., Huang, J.-Y., Yuan, Y.-H., & Chen, N.-H. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.49 · Cited by 208
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
The Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders
Vidoni, C., Follo, C., Savino, M., Melone, M. A. B., & Isidoro, C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21394 · Cited by 164
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.019 · Cited by 114
“The most widely used pharmacological treatments for PD, such as levodopa, modulate brain dopamine (Barbeau, 1974; Connolly and Lang, 2014).”
MethodMolecular Mechanisms Underlying Synaptic and Axon Degeneration in Parkinson’s Disease
Gcwensa, N. Z., Russell, D. L., Cowell, R. M., & Volpicelli-Daley, L. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.626128 · Cited by 110
Moon, J., Teymourian, H., De la Paz, E., Sempionatto, J. R., Mahato, K., Sonsa‐ard, T., Huang, N., Longardner, K., Litvan, I., & Wang, J. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202106674 · Cited by 103
Leyva-Gómez, G., Cortés, H., Magaña, J. J., Leyva-García, N., Quintanar-Guerrero, D., & Florán, B. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.009 · Cited by 102
Pharmacology and Clinical Drug Candidates in Redox Medicine
Dao, V. T.-V., Casas, A. I., Maghzal, G. J., Seredenina, T., Kaludercic, N., Robledinos-Anton, N., Di Lisa, F., Stocker, R., Ghezzi, P., Jaquet, V., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6430 · Cited by 88
Tsao, S.-P., Nurrahma, B. A., Kumar, R., Wu, C.-H., Yeh, T.-H., Chiu, C.-C., Lee, Y.-P., Liao, Y.-C., Huang, C.-H., Yeh, Y.-T., et al. (2021) · Antioxidants · doi:10.3390/antiox10111823 · Cited by 79
Potential Treatment of Parkinson’s Disease with Omega-3 Polyunsaturated Fatty Acids
Li, P., & Song, C. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1735143 · Cited by 74
Zeng, B., & Zhao, K. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12507 · Cited by 64
Yue, M., Wei, J., Chen, W., Hong, D., Chen, T., & Fang, X. (2022) · Nutrients · doi:10.3390/nu14224886 · Cited by 62
Rahimi, F., Samotus, O., Lee, J., & Jog, M. (2015) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.240 · Cited by 55
Metabolic alterations in plasma from patients with familial and idiopathic Parkinson’s disease
Yakhine-Diop, S. M. S., Morales-García, J. A., Niso-Santano, M., González-Polo, R. A., Uribe-Carretero, E., Martinez-Chacon, G., Durand, S., Maiuri, M. C., Aiastui, A., Zulaica, M., et al. (2020) · Aging · doi:10.18632/aging.103992 · Cited by 50
van Kessel, S. P., Bullock, A., van Dijk, G., & El Aidy, S. (2022) · mSystems · doi:10.1128/msystems.01191-21 · Cited by 41
Heart Matters: Cardiac Dysfunction and Other Autonomic Changes in Parkinson’s Disease
Gonçalves, V. C., Cuenca-Bermejo, L., Fernandez-Villalba, E., Martin-Balbuena, S., da Silva Fernandes, M. J., Scorza, C. A., & Herrero, M.-T. (2022) · The Neuroscientist · doi:10.1177/1073858421990000 · Cited by 37
Drobny, A., Ngo, P. A., Neurath, M. F., Zunke, F., & López-Posadas, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.655123 · Cited by 24
Pons-Espinal, M., Blasco-Agell, L., & Consiglio, A. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03700-x · Cited by 18
Panagiotakopoulou, V., Botsakis, K., Delis, F., Mourtzi, T., Tzatzarakis, M. N., Dimopoulou, A., Poulia, N., Antoniou, K., Stathopoulos, G. T., Matsokis, N., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107919 · Cited by 15
Genetic risk of Parkinson’s disease in the general population
Darweesh, S. K. L., Verlinden, V. J. A., Adams, H. H. H., Uitterlinden, A. G., Hofman, A., Stricker, B. H., van Duijn, C. M., Koudstaal, P. J., & Ikram, M. A. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.05.030 · Cited by 13
1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents
Ortíz de Zárate, A., Pérez-Torralba, M., Bonet Isidro, I., López, C., Claramunt, R. M., Martínez-Casanova, D., Sánchez-Vera, I., Jiménez-González, J., & Lavandera, J. L. (2021) · Antioxidants · doi:10.3390/antiox10101584 · Cited by 11
Metadata
- Authors
- Connolly, B. S., & Lang, A. E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-04-23
- Volume
- 311
- Issue
- 16
- Pages
- 1670
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2106350754
- Cited by
- 1,498
- References
- 126
- FWCI
- 68.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.